Veru Q3 net rev $4.0M, net loss $0.07; Phase 2b QUALITY study fully enrolled (>150 pts), topline Jan 2025

VERU INC.

Q3 net revenue $4.0M (up 21% YoY); operating loss $10.9M vs $13.7M.
Net loss $11.0M ($0.07/sh) vs $12.5M ($0.14/sh) prior year.
Phase 2b QUALITY trial full enrollment >150 patients achieved; topline lean body mass data expected Jan 2025.
Cash $29.2M at June 30, 2024 vs $9.6M at Sept 30, 2023.
Enobosarm aims to preserve muscle during GLP-1 weight loss; extension study data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.